 |
Enzon Presents Data From Phase II PEG-SN38 (EZN-2208) Study in Patients With Metastatic Breast Cancer
Dec 8, 2011
|
10.2 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 12/08/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today presented data from a Phase II, open-label study in which PEG-SN38 (EZN-2208) demonstrated notable activity in patients with previously treated metastatic breast cancer. The data were presented in a poster session (Poster P3-16-18) at the San Antoni...
|
|
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting
Nov 12, 2011
|
12.6 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/12/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced the presentation of clinical and preclinical data from three messenger ribonucleic acid (mRNA) product candidates based on the Company's locked nucleic acid (LNA) technology platform at the AACR-NCI-EORTC International Conference: Molecular...
|
|
Enzon Reports 3rd Quarter 2011 Results
Nov 3, 2011
|
51.6 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/03/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2011. For the third quarter of 2011, Enzon reported a loss from continuing operations of $9.1 million, or $0.19 diluted loss per share, as compared to a loss from continuing operations of $8.4...
|
|
Enzon Announces Management Change, Forms Special Committee of the Board
Oct 17, 2011
|
8.8 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 10/17/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that Ana I. Stancic, C.P.A., M.B.A., current Senior Vice President, Finance and Chief Financial Officer, has been promoted to Chief Operating Officer, Principal Executive Officer and Executive Vice President, effective immediately. She wil...
|
|
Enzon Announces Reduction in Force to Align Operations with Research and Development Activities
Sep 22, 2011
|
7.7 KB |
|
| |
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is
implementing a plan to reduce its workforce and operating costs to more
closely align its resources with the Company's research and development
activities.
The reduction in force will...
|
|
Enzon Reports 2nd Quarter 2011 Results
Aug 4, 2011
|
53.3 KB |
|
| |
PISCATAWAY, NJ -- (MARKET WIRE) -- 08/04/11 --
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2011. For the second quarter of 2011, Enzon reported a loss from continuing operations of $7.1 million, or $0.13 diluted loss per share, as compared to a loss from continuing operations of $5...
|
|
ENZON Names Ana I. Stancic Chief Financial Officer
May 31, 2011
|
9.5 KB |
|
| |
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Ana I.
Stancic has been named Senior Vice President and Chief Financial Officer
of the Company, effective June 8, 2011. Ms. Stancic has more than 20
years of extensive and diversified finance, accounting and operat...
|
|
Enzon Announces Discontinuation of PEG-SN38 Program in Metastatic Colorectal Carcinoma in Light of Evolving Standards of Care
May 19, 2011
|
8.5 KB |
|
| |
PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer,
Other Solid Tumors
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that, in
light of evolving standards of care for the treatment of metastatic
colorectal cancer (mCRC), t...
|
|
Enzon Reports 1st Quarter 2011 Results
May 6, 2011
|
62.6 KB |
|
| |
--Investments in R&D translating to continued progress with oncology
pipeline--
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial
results for the first quarter of 2011.
For the first quarter o...
|
|
Enzon Presents Data at 2011 AACR Meeting
Apr 5, 2011
|
50.3 KB |
|
| |
Third-Generation mRNA Antagonists Continue Showing Promise in
Expanding Range of Oncology Indications
Locked Nucleic Acid Technology to be Featured in RNA-Targeting
Therapeutics Symposium
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) ...
|
|
Enzon Appoints Richard Mulligan, Ph.D. Vice-Chairman of the Board; Adopts Majority Vote Standard for Election of Directors
Mar 17, 2011
|
9.4 KB |
|
| |
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Richard
C. Mulligan, Ph.D., has been appointed Vice-Chairman of the Board of
Directors, effective immediately. Dr. Mulligan, the Mallinckrodt
Professor of Genetics at Harvard Medical School and Director of the
...
|
|
Enzon Reports 2010 Results
Feb 17, 2011
|
74.2 KB |
|
| |
Pipeline Development Continues to Advance as Transformation to a
Biotechnology Company is Complete
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its
fourth-quarter and full-year 2010 financial results. For the three
months ended Decem...
|
|
Enzon to Release Fourth Quarter 2010 Earnings on Thursday, February 17, 2011; Conference Call and Webcast to Follow
Feb 10, 2011
|
7.0 KB |
|
| |
PISCATAWAY, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it will
report its financial results for the quarter ended December 31, 2010, on
Thursday, February 17, 2011 at 4:00 pm Eastern Time (ET). The release
will be followed by a live conference call, which will begin at...
|
|
Enzon to Begin Phase 1 Study of Novel Androgen Receptor mRNA Antagonist in Castration-Resistant Prostate Cancer
Jan 10, 2011
|
9.9 KB |
|
| |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the
Investigational New Drug (IND) approval by the US Food and Drug
Administration (FDA) and plan to commence enrollment into a Phase 1a/1b
study shortly. The study will evaluate the safety and tolerability of
...
|
|
Enzon Board Authorizes Share Repurchase Program
Dec 21, 2010
|
8.0 KB |
|
| |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the
Company’s Board of Directors has authorized the purchase of up to $200
million of outstanding shares of the Company’s common stock. No date was
established for completion of the share repurchase program. The
...
|
|
Enzon Announces the Initiation of Two Phase I Studies in Collaboration with the National Cancer Institute
Dec 15, 2010
|
48.0 KB |
|
| |
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced the
initiation of Phase I clinical studies, in collaboration with the
National Cancer Institute (NCI), for two of the Company’s novel oncology
product candidates, EZN-2968 and EZN-2208 (PEG-SN38). Both EZN-2968 and
...
|
|
Enzon Presents Data at 2010 EORTC-NCI-AACR Meeting
Nov 17, 2010
|
49.2 KB |
|
| |
Third-Generation mRNA-Targeting Compounds Show Potent Anti-Tumor
Activity
BRIDGEWATER, N.J.--(BUSINESS WIRE)--
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today presented data from
preclinical studies of three investigational messenger RNA (mRNA)
antagonists. These antagonists are ba...
|
|
Enzon Reports Third Quarter 2010 Results
Nov 2, 2010
|
23.7 KB |
|
| |
BRIDGEWATER, N.J., Nov 02, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial
results for the third quarter of 2010. Enzon reported a loss from
continuing operations of $8.4 million or $0.14 per diluted share, as
compared to a loss of $11.5 million or $0.26 per diluted share for ...
|
|
Enzon Pharmaceuticals Awarded $1.2 Million in Grants under QTDP Program
Nov 2, 2010
|
7.8 KB |
|
| |
BRIDGEWATER, N.J., Nov 02, 2010 (BUSINESS WIRE) -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that it has
been awarded $1.2 million in funding under the IRS Qualifying
Therapeutic Discovery Project (QTDP) program, which was created by
Congress as part of the Patient Protection and Affordable Care Act of
...
|
|
CORRECTING and REPLACING Abstracts Highlighting Data from Enzon's mRNA Antagonist Programs Accepted for Presentation at 2010 EORTC-NCI-AACR Meeting
Oct 29, 2010
|
9.0 KB |
|
| |
BRIDGEWATER, N.J., Oct 29, 2010 (BUSINESS WIRE) -- Second graph of release, the time zones should be CET. (sted, CEST).
The corrected release reads:
ABSTRACTS HIGHLIGHTING DATA FROM ENZON'S MRNA ANTAGONIST PROGRAMS
ACCEPTED FOR PRESENTATION AT 2010 EORTC-NCI-AACR MEETING
Novel mRNA Antagonist Compounds Based on Locked Nucleic Acid
...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz